Top Markets
#1 MarsCoin MarsCoin +37.64%
#2 Palladium Network Palladium Network +27.94%
#3 Siren Siren +26.04%
#4 Status Status +24.20%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#6 BankrCoin BankrCoin +15.09%
#7 ICON ICON +15.04%
#8 Useless Coin Useless Coin +11.93%
#9 Ankr Network Ankr Network +11.88%
#10 Bedrock Bedrock +11.87%
Coin of the day
MarsCoin MarsCoin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPH
Classifica tra le azioni #18401
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Prezzo delle azioni
$2.13
Ultima sincronizzazione: 2026-09-02
Capitalizzazione di mercato
$200.27M
Variazione (1 giorno)
0.90%
Variazione (1 anno)
-1.67%
Paese
FR
Scambia Innate Pharma S.A. (IPH)

Categoria

Healthcare
Il prezzo IPH con la capitalizzazione del mercato della B
Innate Pharma S.A. Innate Pharma S.A.
IPH
$2.13
Capitalizzazione di mercato di Innate Pharma S.A.(IPH)
Capitalizzazione di mercato: $200.27M
A partire dal September 2026, Innate Pharma S.A. ha una capitalizzazione di mercato pari a $200.27M. Questo rende Innate Pharma S.A. la 18401st azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Innate Pharma S.A. dal 2006 al 2026
IPH in paragone con la classifica dei più popolari stocks
Il prezzo per IPH Attivo B Capitalizzazione del mercato a B Risultati
Innate Pharma S.A. Innate Pharma S.A.
$57,764.65 $200.27M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.424T +2,708,413.32%
Innate Pharma S.A. Innate Pharma S.A.
$50,859.62 $200.27M
Apple Inc. Apple Inc.
AAPL
$4.776T +2,384,644.92%
Innate Pharma S.A. Innate Pharma S.A.
$43,148.78 $200.27M
Alphabet Inc. Alphabet Inc.
GOOG
$4.052T +2,023,093.00%
Innate Pharma S.A. Innate Pharma S.A.
$39,306.80 $200.27M
Microsoft Corporation Microsoft Corporation
MSFT
$3.691T +1,842,947.23%
Innate Pharma S.A. Innate Pharma S.A.
$29,224.14 $200.27M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.744T +1,370,183.82%